

## Consolidated Profit and Loss Account

For the quarter ended 30 September 2000	Continuing Operations			Discontinued Operations	Total
	Ongoing operations \$m	Operations to be discontinued \$m	Exceptional items \$m	\$m	\$m
<b>Sales</b>	3,797	497	-	-	4,294
Cost of sales	(961)	(301)	-	-	(1,262)
Distribution costs	(48)	(18)	-	-	(66)
Research and development	(631)	(71)	(1)	-	(703)
Selling, general and administrative expenses	(1,242)	(110)	(42)	-	(1,394)
Other operating income	52	12	-	-	64
<b>Group operating profit</b>	967	9	(43)	-	933
Share of joint venture and associates' operating profits/(losses)	(12)	-	-	-	(12)
Net interest	22	-	-	-	22
<b>Profit on ordinary activities before taxation</b>	977	9	(43)	-	943
Taxation	(287)	(4)	12	-	(279)
<b>Profit on ordinary activities after taxation</b>	690	5	(31)	-	664
Attributable to minorities	(5)	-	-	-	(5)
<b>Net profit for the period</b>	685	5	(31)	-	659
Dividends to Shareholders	-	-	-	-	-
<b>Profit retained for the period</b>	685	5	(31)	-	659
Earnings per Ordinary Share before exceptional items	\$0.39	-	-	-	\$0.39
Earnings per Ordinary Share	\$0.39	-	\$(0.02)	-	\$0.37
Diluted earnings per Ordinary Share	\$0.39	-	\$(0.02)	-	\$0.37
Weighted average number of Ordinary Shares in issue (millions)					1,766
Diluted average number of Ordinary Shares in issue (millions)					1,768

## Consolidated Profit and Loss Account

For the quarter ended 30 September 1999	Continuing Operations			Discontinued Operations	Total
	Ongoing operations \$m	Operations to be discontinued \$m	Exceptional items \$m	\$m	\$m
<b>Sales</b>	3,787	492	-	15	4,294
Cost of sales	(1,145)	(292)	(5)	(14)	(1,456)
Distribution costs	(57)	(20)	-	-	(77)
Research and development	(589)	(75)	(12)	(1)	(677)
Selling, general and administrative expenses	(1,074)	(119)	(197)	(4)	(1,394)
Other operating income	32	9	-	-	41
<b>Group operating profit</b>	954	(5)	(214)	(4)	731
Share of joint venture and associates' operating profits/(losses)	(17)	-	-	-	(17)
Profits less losses on sale and closure of operations	-	-	-	-	-
Merger costs	-	-	-	-	-
Net interest	9	-	-	-	9
<b>Profit on ordinary activities before taxation</b>	946	(5)	(214)	(4)	723
Taxation	(284)	2	44	1	(237)
<b>Profit on ordinary activities after taxation</b>	662	(3)	(170)	(3)	486
Attributable to minorities	(1)	(1)	-	-	(2)
<b>Net profit for the period</b>	661	(4)	(170)	(3)	484
Dividends to Shareholders	-	-	-	-	-
<b>Profit/(loss) retained for the period</b>	661	(4)	(170)	(3)	484
Earnings per Ordinary Share before exceptional items	\$0.37	-	-	-	\$0.37
Earnings per Ordinary Share	\$0.37	-	\$(0.10)	-	\$0.27
Diluted earnings per Ordinary Share	\$0.37	-	\$(0.10)	-	\$0.27
Weighted average number of Ordinary Shares in issue (millions)					1,776
Diluted average number of Ordinary Shares in issue (millions)					1,780

## Consolidated Profit and Loss Account

	Continuing Operations			Discontinued Operations	Total
	Ongoing operations \$m	Operations to be discontinued \$m	Exceptional items \$m	\$m	\$m
<b>For the nine months ended 30 September 2000</b>					
<b>Sales</b>	11,660	2,178	-	-	13,838
Cost of sales	(3,045)	(1,214)	(3)	-	(4,262)
Distribution costs	(168)	(72)	-	-	(240)
Research and development	(1,842)	(203)	(26)	-	(2,071)
Selling, general and administrative expenses	(3,715)	(370)	(193)	-	(4,278)
Other operating income	123	33	-	-	156
<b>Group operating profit</b>	<b>3,013</b>	<b>352</b>	<b>(222)</b>	<b>-</b>	<b>3,143</b>
Share of joint venture and associates' operating profits	7	-	-	-	7
Net interest	56	-	-	-	56
<b>Profit on ordinary activities before taxation</b>	<b>3,076</b>	<b>352</b>	<b>(222)</b>	<b>-</b>	<b>3,206</b>
Taxation	(892)	(138)	43	-	(987)
<b>Profit on ordinary activities after taxation</b>	<b>2,184</b>	<b>214</b>	<b>(179)</b>	<b>-</b>	<b>2,219</b>
Attributable to minorities	(10)	(2)	-	-	(12)
<b>Net profit for the period</b>	<b>2,174</b>	<b>212</b>	<b>(179)</b>	<b>-</b>	<b>2,207</b>
Dividends to Shareholders	(406)	-	-	-	(406)
<b>Profit retained for the period</b>	<b>1,768</b>	<b>212</b>	<b>(179)</b>	<b>-</b>	<b>1,801</b>
Earnings per Ordinary Share before exceptional items	\$1.23	\$0.12	-	-	\$1.35
Earnings per Ordinary Share	\$1.23	\$0.12	\$(0.10)	-	\$1.25
Diluted earnings per Ordinary Share	\$1.23	\$0.12	\$(0.10)	-	\$1.25
Weighted average number of Ordinary Shares in issue (millions)					1,769
Diluted average number of Ordinary Shares in issue (millions)					1,771

## Consolidated Profit and Loss Account

For the nine months ended 30 September 1999	Continuing Operations			Discontinued Operations	Total
	Ongoing operations \$m	Operations to be discontinued \$m	Exceptional items \$m	\$m	\$m
<b>Sales</b>	11,218	2,104	-	630	13,952
Cost of sales	(3,042)	(1,163)	(15)	(394)	(4,614)
Distribution costs	(173)	(71)	-	(29)	(273)
Research and development	(1,761)	(215)	(17)	(44)	(2,037)
Selling, general and administrative expenses	(3,566)	(405)	(324)	(98)	(4,393)
Other operating income	98	28	-	2	128
<b>Group operating profit</b>	<b>2,774</b>	<b>278</b>	<b>(356)</b>	<b>67</b>	<b>2,763</b>
Share of joint venture and associates' operating profits	4	1	-	1	6
Profits less losses on sale and closure of operations	-	-	-	237	237
Merger costs	-	-	(917)	-	(917)
Net interest	(24)	-	-	-	(24)
<b>Profit on ordinary activities before taxation</b>	<b>2,754</b>	<b>279</b>	<b>(1,273)</b>	<b>305</b>	<b>2,065</b>
Taxation	(808)	(98)	282	(121)	(745)
<b>Profit on ordinary activities after taxation</b>	<b>1,946</b>	<b>181</b>	<b>(991)</b>	<b>184</b>	<b>1,320</b>
Attributable to minorities	(2)	(2)	-	-	(4)
<b>Net profit for the period</b>	<b>1,944</b>	<b>179</b>	<b>(991)</b>	<b>184</b>	<b>1,316</b>
Dividends to Shareholders	(408)	-	-	-	(408)
<b>Profit retained for the period</b>	<b>1,536</b>	<b>179</b>	<b>(991)</b>	<b>184</b>	<b>908</b>
Earnings per Ordinary Share before exceptional items	\$1.09	\$0.11	-	\$0.02	\$1.22
Earnings per Ordinary Share	\$1.09	\$0.11	\$(0.56)	\$0.10	\$0.74
Diluted earnings per Ordinary Share	\$1.09	\$0.11	\$(0.56)	\$0.10	\$0.74
Weighted average number of Ordinary Shares in issue (millions)					1,776
Diluted average number of Ordinary Shares in issue (millions)					1,780

## Consolidated Balance Sheet

	30 Sept 2000 \$m	31 Dec 1999 \$m
Fixed assets	9,281	9,902
Current assets	11,166	9,914
<b>Total assets</b>	<b>20,447</b>	<b>19,816</b>
Creditors due within one year	(7,236)	(7,019)
<b>Net current assets</b>	<b>3,930</b>	<b>2,895</b>
<b>Total assets less current liabilities</b>	<b>13,211</b>	<b>12,797</b>
Creditors due after more than one year	(1,169)	(1,202)
Provisions for liabilities and charges	(1,216)	(1,253)
<b>Net assets</b>	<b>10,826</b>	<b>10,342</b>
<b>Capital and reserves</b>		
Shareholders' funds and minority interests	10,826	10,342

## Consolidated Cash Flow Statement

For the nine months ended 30 September	2000 \$m	1999 \$m
<b>Cash flow from operating activities</b>		
Operating profit before exceptional items	3,365	3,119
Depreciation and amortisation	773	781
Increase in working capital and other non-cash movements	(186)	(661)
<b>Net cash inflow from operating activities before exceptional items</b>	<b>3,952</b>	<b>3,239</b>
Outflow related to exceptional items	(623)	(1,111)
<b>Net cash inflow from operating activities</b>	<b>3,329</b>	<b>2,128</b>
Dividends received from joint ventures and associates	-	3
Returns on investments and servicing of finance	(10)	(28)
Tax paid	(587)	(685)
Capital expenditure and financial investment	(1,001)	(2,169)
Acquisitions and disposals	-	1,947
Equity dividends paid to shareholders	(820)	(800)
<b>Net cash inflow before management of liquid resources and financing</b>	<b>911</b>	<b>396</b>
Net (purchase)/issues of shares	(340)	19
Exchange and other movements	(159)	(3)
<b>Increase in net cash funds in the period</b>	<b>412</b>	<b>412</b>
Net cash funds at beginning of period	2,169	2,254
<b>Net cash funds at end of period</b>	<b>2,581</b>	<b>2,666</b>

# Notes to the Interim Financial Statements

## 1 BASIS OF PREPARATION AND ACCOUNTING POLICIES

The interim financial statements have been prepared using the merger method of accounting in relation to the merger of Zeneca Group PLC and Astra AB which became effective on 6 April 1999. Under merger accounting, the results and cash flows of Zeneca Group PLC and Astra AB are combined from the beginning of the financial period in which the merger occurred and their assets and liabilities combined at the amounts at which they were previously recorded after adjusting to achieve consistency of accounting policies.

The unaudited results for the nine months ended 30 September 2000 have been prepared in accordance with UK generally accepted accounting principles. The accounting policies applied are those set out in AstraZeneca PLC's 1999 Annual Report and Form 20-F except that during the period under review AstraZeneca adopted Financial Reporting Standard No. 15 "Tangible Fixed Assets" (FRS15) and Financial Reporting Standard No. 16 "Current Tax" (FRS16). The adoption of FRS15 and FRS16 had no material impact on the Group's results or net assets.

Continuing operations comprises principally the ongoing Healthcare operations and the Group's Agrochemicals business. The latter (excluding the Advanta joint venture) has been classified as 'Operations to be discontinued' following the announcement on 2 December 1999 to merge the business with the agrochemicals business of Novartis to form Syngenta AG. Discontinued operations comprise the Zeneca Specialties business sold on 30 June 1999.

These interim financial statements do not comprise the statutory accounts of the Group. Statutory accounts for AstraZeneca PLC for the year ended 31 December 1999 have been filed with the Registrar of Companies. The auditors' report on those accounts was unqualified and did not contain any statement under Section 237 of the Companies Act 1985.

## 2 JOINT VENTURES AND ASSOCIATES

The Group's share of joint venture sales for the nine months to 30 September 2000 amounted to \$185m and \$197m for the comparative period. Share of joint venture and associates' operating profits for the nine months to 30 September 2000 amounted to \$7m and nil respectively, and for the comparative period \$5m and \$1m, respectively.

## 3 EXCEPTIONAL ITEMS

	3rd Quarter 2000 \$m	3rd Quarter 1999 \$m	Nine Months 2000 \$m	Nine Months 1999 \$m
<b>Exceptional items included in the profit and loss account</b>				
Integration and synergy costs	(43)	(202)	(222)	(332)
Astra Pharmaceuticals L.P. restructuring costs	-	(12)	-	(24)
<b>Exceptional items included in operating profits</b>	(43)	(214)	(222)	(356)
Gain on disposal of Specialties business (after charging \$406m of goodwill previously written off to reserves)	-	-	-	237
<b>Profit less losses on sale and closure of operations</b>	-	-	-	237
Merck 'Trigger Event' payment	-	-	-	(713)
Other merger costs	-	-	-	(204)
<b>Merger costs</b>	-	-	-	(917)
<b>Total exceptional items before taxation</b>	(43)	(214)	(222)	(1,036)
Net taxation credit	12	44	43	185
	(31)	(170)	(179)	(851)

## 4 SEGMENT ANALYSIS

	3rd Quarter 2000 \$m	3rd Quarter 1999 \$m	Nine Months 2000 \$m	Nine Months 1999 \$m
<b>Sales by class of business</b>				
Healthcare	3,774	3,766	11,580	11,148
Other trading	23	21	80	70
Ongoing operations	3,797	3,787	11,660	11,218
Agrochemicals (to be discontinued)	497	492	2,178	2,104
Specialties (discontinued)	-	15	-	630
Group	4,294	4,294	13,838	13,952
<b>Operating profit/(loss) before exceptional items</b>				
Healthcare	975	958	3,033	2,792
Other trading	(8)	(4)	(20)	(18)
Ongoing operations	967	954	3,013	2,774
Agrochemicals (to be discontinued)	9	(5)	352	278
Specialties (discontinued)	-	(4)	-	67
Group	976	945	3,365	3,119
<b>Operating profit/(loss) before exceptional items as a percentage of sales</b>				
	%	%	%	%
Healthcare	25.8	25.4	26.2	25.0
Ongoing operations	25.5	25.2	25.8	24.7

## 5 PRODUCTS AND TERRITORIAL SEGMENT SALES ANALYSIS

	3rd Quarter 2000 \$m	3rd Quarter 1999 \$m	% Growth Constant Currency	Nine Months 2000 \$m	Nine Months 1999 \$m	% Growth Constant Currency
<b>Healthcare</b>						
<b>Gastrointestinal:</b>						
Losec	1,565	1,539	4%	4,532	4,387	6%
Nexium	4	-	-	4	-	-
Others	12	12	-	34	36	-6%
<b>Total Gastrointestinal</b>	<b>1,581</b>	<b>1,551</b>	<b>4%</b>	<b>4,570</b>	<b>4,423</b>	<b>6%</b>
<b>Cardiovascular:</b>						
Zestril	299	322	-5%	960	924	6%
Seloken	144	152	-2%	405	409	3%
Tenormin	110	121	-7%	363	368	-1%
Plendil	120	112	11%	353	328	11%
Atacand	72	43	76%	196	116	80%
Others	106	126	-9%	358	401	-6%
<b>Total Cardiovascular</b>	<b>851</b>	<b>876</b>	<b>1%</b>	<b>2,635</b>	<b>2,546</b>	<b>7%</b>
<b>Respiratory:</b>						
Pulmicort	159	169	-	512	539	1%
Rhinocort	51	38	39%	165	137	25%
Accolate	17	35	-48%	131	109	20%
Bricanyl	28	30	-	94	103	-8%
Oxis	28	22	41%	84	63	46%
Others	12	12	-	38	41	-
<b>Total Respiratory</b>	<b>295</b>	<b>306</b>	<b>2%</b>	<b>1,024</b>	<b>992</b>	<b>9%</b>
<b>Oncology:</b>						
Zoladex	189	161	19%	553	492	13%
Nolvadex	130	142	-8%	405	429	-7%
Casodex	94	79	22%	314	245	31%
Arimidex	35	37	-	117	100	22%
Others	7	6	50%	22	18	45%
<b>Total Oncology</b>	<b>455</b>	<b>425</b>	<b>9%</b>	<b>1,411</b>	<b>1,284</b>	<b>11%</b>
<b>Specialist/Hospital:</b>						
Diprivan	109	137	-17%	393	464	-12%
Xylocaine	58	56	6%	175	184	-4%
Marcaine	22	21	15%	67	63	14%
Seroquel	89	66	35%	293	161	83%
Zomig	46	49	-2%	178	135	34%
Merrem	44	37	22%	122	114	13%
Other Products	152	169	-6%	492	536	-12%
Astra Tech	27	27	7%	85	82	9%
Salick Health Care	45	46	-2%	135	164	-18%
<b>Total Specialist/Hospital</b>	<b>592</b>	<b>608</b>	<b>-</b>	<b>1,940</b>	<b>1,903</b>	<b>3%</b>
<b>Total Healthcare</b>	<b>3,774</b>	<b>3,766</b>	<b>3%</b>	<b>11,580</b>	<b>11,148</b>	<b>7%</b>



## 5 PRODUCTS AND TERRITORIAL SEGMENT SALES ANALYSIS (CONTINUED)

<b>Healthcare</b>	<b>3rd Quarter 2000 \$m</b>	<b>3rd Quarter 1999 \$m</b>	<b>% Growth Constant Currency</b>	<b>Nine Months 2000 \$m</b>	<b>Nine Months 1999 \$m</b>	<b>% Growth Constant Currency</b>
<b>Territorial Analysis</b>						
USA:						
Pharmaceuticals	1,921	1,937	-1%	5,841	5,407	8%
Salick Health Care	45	46	-2%	135	164	-18%
Japan	207	164	16%	581	468	10%
France	212	201	17%	662	624	19%
Germany	175	194	18%	528	643	-7%
Italy	98	121	-9%	417	438	5%
Sweden	70	79	-10%	242	263	-6%
UK	189	198	-2%	527	590	-7%
Rest of World	857	826	8%	2,647	2,551	7%
<b>Total Healthcare</b>	<b>3,774</b>	<b>3,766</b>	<b>3%</b>	<b>11,580</b>	<b>11,148</b>	<b>7%</b>

Constant currency % growth has been calculated excluding the effects arising from exchange rate movements.

<b>Agrochemicals</b>	<b>3rd Quarter 2000 \$m</b>	<b>3rd Quarter 1999 \$m</b>	<b>% Growth Constant Currency</b>	<b>Nine Months 2000 \$m</b>	<b>Nine Months 1999 \$m</b>	<b>% Growth Constant Currency</b>
<b>Product Analysis</b>						
Herbicides:						
Non-Selective	153	164	-4%	621	533	19%
Selective	105	100	8%	555	590	-3%
<b>Total Herbicides</b>	<b>258</b>	<b>264</b>	<b>1%</b>	<b>1,176</b>	<b>1,123</b>	<b>7%</b>
Insecticides	89	100	-7%	359	330	12%
Fungicides	135	115	20%	592	590	5%
Others	15	13	15%	51	61	-23%
<b>Total Agrochemicals</b>	<b>497</b>	<b>492</b>	<b>4%</b>	<b>2,178</b>	<b>2,104</b>	<b>7%</b>
<b>Territorial Analysis</b>						
North America	150	151	-	765	727	5%
Europe	126	122	15%	726	755	6%
Latin America	134	137	-3%	343	302	14%
Asia, Africa, Australasia	87	82	8%	344	320	7%
<b>Total Agrochemicals</b>	<b>497</b>	<b>492</b>	<b>4%</b>	<b>2,178</b>	<b>2,104</b>	<b>7%</b>

Constant currency % growth has been calculated excluding the effects arising from exchange rate movements.

## Shareholder Information

### ANNOUNCEMENTS AND MEETINGS

---

Preliminary announcement of full year results and announcement of second interim dividend	8 February 2001
Annual General Meeting	26 April 2001
Announcement of First Quarter Results	26 April 2001
Announcement of Second Quarter & Half Year Results	26 July 2001
Announcement of Third Quarter & Nine Months Results	24 October 2001

### DIVIDENDS

---

The record date for the first interim dividend payable on 23 October 2000 (in the UK, Sweden and the US) was 8 September 2000. Ordinary Shares traded ex-dividend on the London Stock Exchange from 4 September 2000 and on the Stockholm Stock Exchange from 6 September 2000. ADSs traded ex-dividend on the New York Stock Exchange from 6 September 2000.

Future dividends will normally be paid as follows:

First Interim	Announced in July and paid in late October
Second Interim	Announced in February and paid in late April

### TRADEMARKS

---

All product or brand names included in Note 5 of this Interim Statement and the following names are trademarks of, or licensed to, AstraZeneca PLC or its subsidiary companies:

**Amistar Atacand Plus Gramoxone Prilosec Pulmicort Respules Rapimelt Rhinocort Aqua Symbicort Surpass Toprol-XL**

For simplicity, sales are reported under the above lead brand names, whereas some compounds are sold under several brand names to address separate market niches.

### ADDRESSES FOR CORRESPONDENCE

---

<b>Registrar and Transfer Office</b>	<b>Depository for ADRs</b>	<b>Registered Office</b>	<b>Swedish Central Securities Depository</b>
The AstraZeneca Registrar Lloyds TSB Registrars The Causeway Worthing West Sussex BN99 6DA Tel: (01903) 502 541	Morgan Guaranty Trust Company of New York ADR Service Center PO Box 842006 Boston, MA 02284-2006 Tel: (781) 575 4328	15 Stanhope Gate London W1K 1LN Tel: (020) 7304 5000	VPC AB Box 7822 S-103 97 Stockholm Sweden Tel: (8) 402 9000

### CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

---

In order to utilise the 'Safe Harbor' provisions of the United States Private Securities Litigation Reform Act of 1995, AstraZeneca is providing the following cautionary statement. This Interim Report contains forward-looking statements with respect to the financial condition, results of operations and businesses of AstraZeneca. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and

maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability and the risks related to the difficulty of integrating Astra's and Zeneca's large and complex businesses on a timely basis and realising synergies.